MENLO PARK, Calif.--(

加州门洛公园--(

BUSINESS WIRE

商业热线

)--Andreessen Horowitz (a16z) Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech Ecosystem Venture Fund (“Fund”) seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients’ lives.

)--Andreessen Horowitz（a16z）Bio+Health今天宣布，与礼来公司（Eli Lilly and Company）（“礼来”）合作，成立了一个新成立的同类风险投资基金，以推动更广泛的人类健康创新。生物技术生态系统风险基金（以下简称“基金”）旨在通过投资治疗平台和尖端技术公司来推动医疗保健领域的变革性进展，这些公司可以带来新药和疾病治疗方法来改善患者的生活。

Managed by a16z Bio + Health, the Fund will deploy up to $500 million to invest in companies at all stages - from company creation to growth. The Fund will focus on advancing the development of new medicines, enabling novel modality platforms, and scaling emerging health technologies. As a complementary source of capital to traditional venture funding, the Fund will take a long-term view to enable disruptive companies to realize the full potential of new biological science, engineering technologies, and AI capabilities.

该基金由a16z Bio+Health管理，将部署至多5亿美元，用于投资公司从创建到成长的各个阶段。该基金将重点推动新药的开发，实现新的模式平台，并扩大新兴卫生技术的规模。作为传统风险投资的补充资金来源，该基金将从长远来看，使破坏性公司能够充分发挥新生物科学、工程技术和人工智能能力的潜力。

The Fund aims to foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators..

该基金旨在培养雄心勃勃的生物+健康企业家和创新者的技术生态系统。。

Vineeta Agarwala, M.D., Ph.D, general partner at a16z Bio + Health, stated, “The Biotech Ecosystem Venture Fund seeks to enable visionary founders to create enduring solutions in biotech and healthcare. Combining our strengths as organizations will empower founders with not only the venture backing needed to advance groundbreaking technologies, but also the resources needed to strategically select the most promising application areas for these platforms.

a16z Bio+Health的普通合伙人Vineeta Agarwala医学博士表示：“生物技术生态系统风险基金旨在使有远见的创始人能够在生物技术和医疗保健领域创造持久的解决方案。结合我们作为组织的优势，不仅可以为创始人提供推进开创性技术所需的风险支持，还可以为这些平台战略性地选择最有前途的应用领域所需的资源。

The creation of this new fund signifies a shared passion and commitment with Lilly to deliver truly meaningful change in our ability to treat and care for people living with disease.'.

这一新基金的成立意味着与礼来共同的热情和承诺，将为我们治疗和护理疾病患者的能力带来真正有意义的改变。”。

The Fund leverages the strengths of a16z in sourcing, building, and scaling bio + health companies, and combines it with Lilly’s deep expertise in life science R&D. Beyond contributing all the capital, Lilly will have the ability to provide additional resources to the companies, including Catalyze360.

该基金利用a16z在寻找、建立和扩大生物+健康公司方面的优势，并将其与礼来在生命科学研发方面的深厚专业知识相结合。除了贡献所有资金外，礼来还将有能力为这些公司提供额外资源，包括Catalyste360。

™

™

which is a specialized support structure for biotech startups that includes Lilly Ventures, Lilly Gateway Labs

Ⓡ

Ⓡ

, and Lilly ExplorR&D

，以及Lilly Explorer研发

™

™

– all of which provide biotech startups with access to world-class pre-clinical and clinical drug development talent and resources. Together, a16z’s distinct experience at the intersection of life sciences and technology, and Lilly’s scientific, clinical, and commercial expertise create an alliance powered to overcome complex challenges within the healthcare ecosystem..

–所有这些都为生物技术初创公司提供了世界一流的临床前和临床药物开发人才和资源。a16z在生命科学和技术交叉领域的独特经验，以及礼来的科学、临床和商业专业知识，共同构成了一个联盟，能够克服医疗保健生态系统中的复杂挑战。。

'Catalyze360 was created to accelerate the success of emerging biotech startups by providing access to people, tools, capabilities, and expertise that is traditionally hard for early-stage companies to reach,” said Nisha Nanda, Ph.D., group vice president, Catalyze360. “With the Biotech Ecosystem Fund, we can further scale our work to empower entrepreneurs as they work to bring transformative therapies to patients faster.'.

。“通过生物技术生态系统基金，我们可以进一步扩大我们的工作规模，使企业家能够更快地为患者带来变革性疗法。”。

About Andreessen Horowitz (a16z)

关于安德森·霍洛维茨（a16z）

Founded in Silicon Valley in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz (known as 'a16z') is a venture capital firm that backs bold entrepreneurs building the future through technology. We are stage agnostic: We invest in seed to venture to late-stage technology companies, across bio + health, consumer, crypto, enterprise, fintech, games, and companies building toward American dynamism.

安德鲁·安德森·霍洛维茨（AndreessenHorowitz，简称“a16z”）于2009年由马克·安德森（MarcAndreessen）和本·霍洛维茨（BenHorowitz）在硅谷成立，是一家风险投资公司，支持大胆的企业家通过技术建设未来。我们不分阶段：我们投资种子公司，向生物+健康、消费者、加密、企业、金融科技、游戏和建立美国活力的公司等晚期技术公司投资。

a16z has $44B in committed capital across multiple funds. The Bio + Health practice invests in bold entrepreneurs who are innovating new ways to treat and tackle diseases and building the modern, efficient and enduring healthcare system for better care..

a16z在多个基金中拥有440亿美元的承诺资本。生物+健康实践投资于大胆的企业家，他们正在创新治疗和应对疾病的新方法，并建立现代，高效和持久的医疗保健系统，以获得更好的护理。。